$ANAB News

Forte Biosciences: Targeting Celiac Disease

UBS Maintains Buy on AnaptysBio, Raises Price Target to $76

Barclays Maintains Overweight on AnaptysBio, Raises Price Target to $75

AnaptysBio Q1 EPS $(1.84) Misses $(0.92) Estimate, Sales $25.556M Miss $28.973M Estimate

AnaptysBio Appoints Christopher Murphy CFO

TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View

AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

Piper Sandler Maintains Overweight on AnaptysBio, Lowers Price Target to $93

AnaptysBio (ANAB) Is Up 13.4% After Court Upholds Jemperli Royalty Rights In Tesaro Dispute

AnaptysBio (NASDAQ:ANAB) Passes Minervini Trend Template and High Growth Momentum Screen

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

Leerink Partners Maintains Outperform on AnaptysBio, Raises Price Target to $85

AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?

AnaptysBio shares are trading higher after a Delaware Chancery Court ruled in favor of the company in a breach of contract claim and left the current royalty rates paid to the company intact.

AnaptysBio shares are trading higher after a Delaware Chancery Court ruled in favor of the company in a breach of contract claim and left the current royalty rates paid to the company intact.

GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim

Delaware Chancery Court Rules In Favor Of Anaptys By Dismissing Tesaro's Anticipatory Breach Claim; Court Ruling Preserves Current Royalty Rates And Rejects Tesaro's Royalty Reduction Request